Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers

Abstract

Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.

Keratinocyte Growth Factor Administration Attenuates Murine Pulmonary Mycobacterium tuberculosis Infection through Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF)-dependent Macrophage Activation and Phagolysosome Fusion

“…The Food and Drug Administration approved the use of KGF for chemotherapy-induced mucositis in December of 2004 (39). Clinical trials with KGF demonstrated reduced duration of oral lesions and salivary gland toxicity in patients with head and neck cancers treated with chemoradiation, diminished duration and severity of mucositis during bone marrow transplantation conditioning, and reduced incidence and severity of mucositis after chemotherapy for metastatic colorectal carcinoma (reviewed by Barasch et al (40).…”

Enhancing T cell reconstitution after hematopoietic stem cell transplantation: A brief update of the latest trends

“…KGF has been shown to be a protective factor for oral mucositis in randomized clinical trial in patients with autologous HSCT [59]. It is currently in clinical trials to assess its effects on GVHD, mucositis and T cell reconstitution in HSCT recipients.…”

Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial

“…For survivors only to day 90 (n=42), the duration of ventilation was increased in the KGF group (16 [13-30] versus 11 [8][9][10][11][12][13][14][15][16] days; P = 0·002). In addition, in the KGF group compared to the placebo group the duration of ICU stay (22 [14-34] versus 12 [10][11][12][13][14][15][16][17][18][19] days; P = 0·001) and hospital stay (Table 4) were also increased From randomization to day 90, the probability of survival (online supplement Figure e1a) or breathing without assistance (online supplement Figure e1b) was higher in the placebo group.…”

“…There was no significant difference between the two groups in OI at day 7 (the primary outcome) or in any other secondary physiological outcomes. The KGF group, compared to placebo, had fewer median ventilatorfree days (1 [0-17] versus 20 [13][14][15][16][17][18][19][20][21][22] days; difference -8 days, 95% CI -17--2; P < 0·001), a longer median duration of ventilation in survivors (16 [13-30] versus 11 [8][9][10][11][12][13][14][15][16] days; difference 6 days, 95% CI 2-14; P = 0·002) and a higher mortality at 28 days (31·0% versus 9·7%; risk ratio 3·2 95% CI 1·0-10·7; P = 0·054).…”

“…promotes epithelial migration, differentiation and epithelial wound healing (William McKeown, Hyland et al 2003;Spielberger, Stiff et al 2004;Shannon, McKeown et al 2006). 3. increases surfactant protein production.…”